Whalesbook
Eli Lilly and Company (India)'s diabetes and weight-loss drug Mounjaro (tirzepatide) has achieved remarkable success, generating Rs 450 crore in sales within seven months, surpassing established drugs. The company highlights its dual-action mechanism, strategic partnerships with entities like Apollo and Cipla, and patient education as key drivers. Eli Lilly is also investing over $1 billion in India for manufacturing and R&D, signaling a strong commitment to the Indian market, and plans to launch new therapies like orforglipron.